Emergency use authorization of the Johnson & Johnson COVID-19 vaccine, the third now available in the United States, has led to questions about which shot is the best. But comparing COVID-19 vaccine efficacies can be misleading, said Jeffrey Carson, a Distinguished Professor of Medicine at Rutgers Robert Wood Johnson Medical School and principal investigator at Rutgers for the Johnson & Johnson trial, which was the second-largest in the country. In clinical trials, the Moderna and Pfizer-BioNTech vaccines were shown to be about 95 percent effective against COVID-19, while Johnson & Johnson’s vaccine was 66.3 percent effective against COVID-19 globally and 72 percent effective against the disease in the United States. To read the full story.